FARYDAK is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Panobinostat Lactate.
Product ID | 0078-0652_1de1e12a-af22-4b99-9116-585bcfc1e304 |
NDC | 0078-0652 |
Product Type | Human Prescription Drug |
Proprietary Name | FARYDAK |
Generic Name | Panobinostat |
Dosage Form | Capsule |
Route of Administration | ORAL |
Marketing Start Date | 2015-02-23 |
Marketing End Date | 2021-01-31 |
Marketing Category | NDA / NDA |
Application Number | NDA205353 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | PANOBINOSTAT LACTATE |
Active Ingredient Strength | 20 mg/1 |
Pharm Classes | Histone Deacetylase Inhibitor [EPC],Histone Deacetylase Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA] |
NDC Exclude Flag | N |
Marketing Start Date | 2015-02-23 |
Marketing End Date | 2022-12-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA205353 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2015-02-23 |
Marketing End Date | 2022-12-31 |
Ingredient | Strength |
---|---|
PANOBINOSTAT LACTATE | 20 mg/1 |
SPL SET ID: | 7774972a-eeaa-4b9a-9e56-3fc1b968e86a |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0650 | FARYDAK | panobinostat |
0078-0651 | FARYDAK | panobinostat |
0078-0652 | FARYDAK | panobinostat |
73116-100 | FARYDAK | panobinostat |
73116-101 | FARYDAK | panobinostat |
73116-102 | FARYDAK | panobinostat |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
FARYDAK 86140638 4765286 Live/Registered |
SECURA BIO, INC. 2013-12-11 |
FARYDAK 79050673 3502071 Live/Registered |
Secura Bio, Inc. 2008-02-01 |